Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Crohn Disease HELP
Based on 13,442 articles published since 2009
||||

These are the 13442 published articles about Crohn Disease that originated from Worldwide during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
326 Editorial Rifaximin in the treatment of inflammatory bowel disease. 2011

Guslandi, Mario. · ·World J Gastroenterol · Pubmed #22180705.

ABSTRACT: The gut microbiota plays a role in promoting and maintaining inflammation in inflammatory bowel diseases (IBD), hence the rationale for the use of antibiotics in the treatment of those disorders. Antibiotics, however, may induce untoward effects, especially during long-term therapy. Rifaximin α polymer is an antibacterial agent that is virtually unabsorbed after oral administration and is devoid of systemic side effects. Rifaximin has provided promising results in inducing remission of Crohn's disease (up to 69% in open studies and significantly higher rates than placebo in double blind trials) and ulcerative colitis (76% in open studies and significantly higher rates than placebo in controlled studies) and might also have a role in maintaining remission of ulcerative colitis and pouchitis. The potential therapeutic activity of rifaximin in IBD deserves to be further investigated and confirmed in larger, controlled studies. The optimal dosage still needs to be better defined.

327 Editorial Editorial: bugs and drugs: insights into the pathogenesis of inflammatory bowel disease. 2011

Nguyen, Geoffrey C. · ·Am J Gastroenterol · Pubmed #22138941.

ABSTRACT: The dysbiosis hypothesis posits that perturbations in the gut microbiome may contribute to the development of inflammatory bowel disease (IBD). A recent Canadian population-based study has shown an association between new-onset IBD and antibiotic use in the 2-5 years preceding diagnosis. Though these findings do not establish a causal relationship, it supports the role of dysbiosis in the pathogenesis of IBD. Furthermore, the study reinforces the importance of the judicious use of antibiotics.

328 Editorial Environmental factors associated with Crohn's disease in India-there's more to it than meets the eye. 2011

Dhar, Anjan. · ·Indian J Gastroenterol · Pubmed #22134791.

ABSTRACT: -- No abstract --

329 Editorial Haematopoietic stem cell autotransplantation for refractory Crohn's disease: ready for prime time? 2011

Buisson, Anthony / Peyrin-Biroulet, Laurent. · ·Dig Liver Dis · Pubmed #22000159.

ABSTRACT: -- No abstract --

330 Editorial [Analysis of total cost of treatment of patients with inflammatory bowel diseases]. 2011

Lazebnik, L B / Parfenov, A I / Guseĭnzade, M G / Kniazev, O V / Efremov, L I. · ·Eksp Klin Gastroenterol · Pubmed #21919238.

ABSTRACT: The article stresses that among the chronic diseases of the digestive tract occupy a special place inflammatory bowel disease (IBD)--UC and BC with multiple complications and the onset of early disability of patients. IBD is a serious issue of gastroenterology, since their etiology remains unknown, and specific treatment hasn't yet been developed. Finally, the prevalence and social significance of IBD also occupy a leading place among the diseases of the digestive organs, since they are characterized by recurrent course and have adverse medical and social prognosis. According to sources in various countries annually spend huge money for treatment of IBD. The costs of IBD depends on the severity and nature of complications, duration of illness, the choice of treatment, frequency of hospitalization and the patient's country of residence. Various studies demonstrate the feasibility of using more modern efficient methods of treatment (MSSC + therapy) to reduce the incidence of complications associated with IBD, resulting in huge costs.

331 Editorial Estimating benefits of therapy in Crohn's disease in terms of indirect costs. 2011

Ghosh, Subrata. · ·Can J Gastroenterol · Pubmed #21912764.

ABSTRACT: -- No abstract --

332 Editorial Targeting opioid signaling in Crohn's disease: new therapeutic pathways. 2011

Zagon, Ian S / McLaughlin, Patricia J. · ·Expert Rev Gastroenterol Hepatol · Pubmed #21910569.

ABSTRACT: -- No abstract --

333 Editorial 'Red alert' or not? - do we give our inflammatory bowel disease patients the right dietary recommendations? 2011

Rogler, Gerhard. · ·Digestion · Pubmed #21865748.

ABSTRACT: -- No abstract --

334 Editorial Natural history of Crohn's disease: is the tide beginning to turn? 2011

Maoláin, M O / Egan, L J. · ·Ir Med J · Pubmed #21671517.

ABSTRACT: -- No abstract --

335 Editorial Granulocyte-macrophage colony stimulating factor and inflammatory bowel disease: establishing a connection. 2011

Dranoff, Glenn. · ·Gastroenterology · Pubmed #21620840.

ABSTRACT: -- No abstract --

336 Editorial Perianal Crohn's disease: is there something new? 2011

Ruffolo, Cesare / Citton, Marilisa / Scarpa, Marco / Angriman, Imerio / Massani, Marco / Caratozzolo, Ezio / Bassi, Nicolò. · ·World J Gastroenterol · Pubmed #21528071.

ABSTRACT: Perianal lesions are common in patients with Crohn's disease, and display aggressive behavior in some cases. An accurate diagnosis is necessary for the optimal management of perianal lesions. Treatment of perianal Crohn's disease includes medical and/or surgical options. Recent discoveries in the pathogenesis of this disease have led to advances in medical and surgical therapy with good results. Perianal lesions in Crohn's disease remain a challenging aspect for both gastroenterologists and surgeons and lead to a greatly impaired quality of life for all patients affected by this disease. A multidisciplinary approach is mandatory to obtain the best results.

337 Editorial Vitamin D--new recommendations worthy of our consideration. 2011

Anonymous1020693. · ·JPEN J Parenter Enteral Nutr · Pubmed #21527591.

ABSTRACT: -- No abstract --

338 Editorial Nutrients and gut health. 2011

Meier, Rémy. · ·Digestion · Pubmed #21494039.

ABSTRACT: -- No abstract --

339 Editorial Choosing the right cross-sectional imaging technique: trading image quality for radiation risk. 2011

Al-Hawary, Mahmoud M / Zimmermann, Ellen M. · ·Inflamm Bowel Dis · Pubmed #21484960.

ABSTRACT: -- No abstract --

340 Editorial Air pollution and the inflammatory bowel diseases. 2011

Kaplan, Gilaad. · ·Inflamm Bowel Dis · Pubmed #21351198.

ABSTRACT: -- No abstract --

341 Editorial Confocal laser endomicroscopy: is it prime time? 2011

Othman, Mohamed O / Wallace, Michael B. · ·J Clin Gastroenterol · Pubmed #21307697.

ABSTRACT: -- No abstract --

342 Editorial Is this stricture inflammatory? 2011

Rogler, Gerhard. · ·Digestion · Pubmed #21273774.

ABSTRACT: -- No abstract --

343 Editorial Inflammation: an equal-opportunity process. 2011

Sachar, David B. · ·Dig Dis Sci · Pubmed #21264510.

ABSTRACT: -- No abstract --

344 Editorial Update on the heritability of inflammatory bowel disease: the importance of twin studies. 2011

Brant, Steven R. · ·Inflamm Bowel Dis · Pubmed #20629102.

ABSTRACT: -- No abstract --

345 Editorial Crohn's disease, feeling well or healthy? 2010

Casellas, F. · ·Rev Esp Enferm Dig · Pubmed #21142381.

ABSTRACT: -- No abstract --

346 Editorial On the second ECCO Consensus on Crohn's disease. 2010

Travis, Simon / Van Assche, Gert / Dignass, Axel / Cabré, Eduard / Gassull, Miquel A. · ·J Crohns Colitis · Pubmed #21122487.

ABSTRACT: -- No abstract --

347 Editorial Prevention of recurrence after surgery for Crohn's disease: efficacy of infliximab. 2010

Yamamoto, Takayuki. · ·World J Gastroenterol · Pubmed #21086556.

ABSTRACT: After surgery for Crohn's disease (CD), early endoscopic lesions are frequently observed despite no symptomatic recurrence. The severity of lesions found at postoperative endoscopy is reported to be a strong predictive factor for future clinical recurrence. If endoscopic lesions in the early postoperative period can be reduced with medications, symptomatic recurrence will likely be delayed and decreased. Before the introduction of biologic therapies, various medications were used for the maintenance of clinical remission after surgery; however, few demonstrated consistent efficacy. Infliximab is a recombinant anti-tumor necrosis factor-α antibody. Although infliximab is one of the most effective medications in the management of CD, its efficacy for early endoscopic lesions after surgery has not yet been assessed. The author and colleagues recently conducted a prospective study in order to investigate the impact of infliximab on early endoscopic lesions after resection for CD. We found that infliximab therapy showed clear suppressive effects on clinical and endoscopic disease activity in patients with early endoscopic lesions after resection.

348 Editorial Barium imaging of the small bowel in Crohn's disease. 2010

Kirwadi, Anand / Hampton, James. · ·Colorectal Dis · Pubmed #21070556.

ABSTRACT: -- No abstract --

349 Editorial Crohn's disease susceptibility gene interactions, a NOD to the newcomer ATG16L1. 2010

Cadwell, Ken. · ·Gastroenterology · Pubmed #20875485.

ABSTRACT: -- No abstract --

350 Editorial Is resection of Crohn's disease a procedure of the past? 2010

Michelassi, Fabrizio. · ·World J Surg · Pubmed #20857107.

ABSTRACT: -- No abstract --

Back · Next